David H. Harpole
- Pulmonary and Respiratory Medicine top 0.05%
- Oncology top 0.5%
- Surgery top 0.5%
- Radiology, Nuclear Medicine and Imaging top 0.5%
- Molecular Biology top 10%
- Co-authors
- Thomas A. D’AmicoJames E. HerndonMark W. OnaitisWilliam R. BurfeindMark F. BerryBetty C. TongEric M. TolozaWalter G. Wolfe
- Topics
- Lung Cancer Diagnosis and Treatment (101 papers)Lung Cancer Treatments and Mutations (75 papers)Esophageal Cancer Research and Treatment (31 papers)
- Partner nations
- United StatesUnited KingdomJapan
In The Last Decade
David H. Harpole
200 papers receiving 12.5k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Pulmonary and Respiratory Medicine 9.1k
- Oncology 3.8k
- Surgery 3.3k
- Radiology, Nuclear Medicine and Imaging 1.5k
- Molecular Biology 1.1k
Countries citing papers authored by David H. Harpole
This map shows the geographic impact of David H. Harpole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Harpole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Harpole more than expected).
Fields of papers citing papers by David H. Harpole
This network shows the impact of papers produced by David H. Harpole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Harpole. The network helps show where David H. Harpole may publish in the future.
Co-authorship network of co-authors of David H. Harpole
This figure shows the co-authorship network connecting the top 25 collaborators of David H. Harpole. A scholar is included among the top collaborators of David H. Harpole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Harpole. David H. Harpole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 55 | |
| 2 | 5 | |
| 3 | 53 | |
| 4 | 7 | |
| 5 | 39 | |
| 6 | 3 | |
| 7 | 49 | |
| 8 | 9 | |
| 9 | 4 | |
| 10 | 62 | |
| 11 | 25 | |
| 12 | 19 | |
| 13 | 30 | |
| 14 | Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groupsbreakdown → | 690 |
| 15 | 214 | |
| 16 | Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. | 199 |
| 17 | 23 | |
| 18 | A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. | 252 |
| 19 | 62 | |
| 20 | 7 |
About David H. Harpole
David H. Harpole is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology, having authored 203 papers that have together received 12.8k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (101 papers), Lung Cancer Treatments and Mutations (75 papers) and Esophageal Cancer Research and Treatment (31 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (9.1k citations), Oncology (3.8k citations) and Microbiology (79 citations). David H. Harpole has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Thomas A. D’Amico, James E. Herndon, Mark W. Onaitis, William R. Burfeind, Mark F. Berry, Betty C. Tong, Eric M. Toloza, Walter G. Wolfe, Rebecca P. Petersen and David J. Sugarbaker. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.